• Latest Posts

Medigene plans to fund its T-cell program with €50 Millions

Pluristem accelerates its Cell Therapy program thanks to the EMA

US-based Juno Therapeutics purchased a German biotech

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

[UPDATE] Adaptimmune raised €156.7M in its IPO

Important Bilateral Academic Agreement for the Future of iPS Cell Therapy


Promethera Biosciences Raised €25,33M to Treat Liver Diseases

Boost for dementia gene-based therapies

Athersys to restructure – 70% of workforce to go

Evotec adds cell therapy manufacturing facility through Rigenerand takeover

TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease